3-rx.comCustomer Support
3-rx.com
   
HomeAbout UsFAQContactHelp
News Center
Health Centers
Medical Encyclopedia
Drugs & Medications
Diseases & Conditions
Medical Symptoms
Med. Tests & Exams
Surgery & Procedures
Injuries & Wounds
Diet & Nutrition
Special Topics



\"$alt_text\"');"); } else { echo"\"$alt_text\""; } ?>


Join our Mailing List





Syndicate

You are here : 3-RX.com > Home > Allergies - Drug News - Immunology -

Daily asthma meds keep lungs in play during exercise

Allergies • • Drug News • • ImmunologyFeb 29, 08

Taking asthma medication daily can help prevent the tightening of the airways or “bronchoconstriction” with physical exertion that affects many children with asthma, a new study from Poland confirms.

Dr. Iwona Stelmach of N. Copernicus Hospital in Lodz and colleagues found that of the four treatments they evaluated, the two including the anti-asthma drug montelukast (Singulair) were the most effective, but all were better than placebo.

“Control of childhood asthma with exercise-induced bronchoconstriction can be obtained by using regular controller treatment,” Stelmach and colleagues write in the Journal of Allergy and Clinical Immunology.

Children may often forget to take bronchodilators before exercising, the researchers note, but daily medications can also help make airways less hyperresponsive to exertion, and don’t have to be taken right before children exercise.

The researchers compared the effectiveness of four different daily treatment approaches: budesonide (Pulmicort turboinhlaer) and formoterol (Oxis turboinhaler); budesonide and montelukast; montelukast alone; and budesonide alone.

They randomized 100 children with exercise-induced bronchoconstriction to one of the treatments or placebo for four weeks. All of the children had a treadmill exercise test before and after treatment.

All children who received active asthma treatment showed a significant reduction in exercise-induced airway tightening, but improvements were greatest in the montelukast-only and montelukast-plus-budesonide groups.

There was no difference between the two montelukast groups, suggesting that budesonide didn’t have an additional effect. However, the researchers say, this could have been because the study was too small to detect the difference.

“It can be argued that adding montelukast should be recommended to achieve better control of exercise-induced bronchoconstriction in children with asthma,” they conclude.

SOURCE: Journal of Allergy and Clinical Immunology, February 2008.



Print Version
Tell-a-Friend
comments powered by Disqus

RELATED ARTICLES:
  New biomarkers may influence drug design and alternative treatments of cancer, study shows
  UGA ecologist finds another cause of antibiotic resistance
  New drug for neuroblastoma shows promise in phase I study
  Drug prevents passage of HBV during pregnancy
  Designing better medical implants
  Baclofen shows promise in patients with alcohol-induced liver disease
  Cell-associated HIV mucosal transmission: The neglected pathway
  Findings point to an ‘off switch’ for drug resistance in cancer
  Stopping statins may benefit terminally ill patients
  Scientists discover potential new target for cancer immunotherapy
  Cholesterol drug users may use pills as a license to overeat
  Study ties breathing problems, asthma to bone loss

 












Home | About Us | FAQ | Contact | Advertising Policy | Privacy Policy | Bookmark Site